Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorVerve Therapeutics, Inc.
About this trial
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.
VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Eligibility criteria
Qualifiers
Refractory hypercholesterolemia
Refractory hypertriglyceridemia
Disqualifiers
Active or history of chronic liver disease
Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
Clinically significant or abnormal laboratory values as defined by the protocol
Trial design
Treatments tested in this trial
- VERVE-201
Treatment groups
36 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov